Other Events ·
HUTCHMED initiates global Phase Ia clinical trial for HMPL-A830, a first-in-class KRAS inhibitor antibody-targeted therapy conjugate
HCMHUTCHMED (China) Ltd
HUTCHMED (China) Limited announced the initiation of a global Phase Ia clinical trial for HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor payload with an anti-EGFR antibody. The first patient received dosing on September 24, 2026, in China, as part of a multicenter study evaluating safety and efficacy in unresectable solid tumors. This development follows an exclusive license agreement signed on September 3, 2026, with a GSK subsidiary for worldwide rights outside Greater China, subject to customary closing conditions including antitrust reviews. HUTCHMED operates in the biopharmaceutical industry, focusing on the discovery and commercialization of targeted cancer therapies.